Emerging Trends in Targeted Molecular Therapies for Inflammatory Bowel Disease: Biologics and Small Molecules

Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic Inflammatory Bowel Diseases (IBD) characterized by complex immune dysregulation and multifactorial pathogenesis. Conventional therapies often show limited efficacy and are associated with substantial adverse effects. This review highlights recent advancements in targeted molecular therapies for IBD, emphasizing biologics, small molecules, and emerging delivery technologies.

A comprehensive literature search was conducted across the PubMed, Scopus, and Web of Science databases, focusing on studies published within the last 7 years. Relevant data on therapeutic mechanisms, clinical efficacy, safety, and cost-effectiveness were systematically extracted and critically analyzed.

Biologic therapies, including anti-TNF agents (infliximab, adalimumab), integrin inhibitors (vedolizumab), and interleukin inhibitors (ustekinumab, risankizumab), have demonstrated significant improvements in remission and mucosal healing. However, challenges such as immunogenicity, loss of response, and high treatment costs persist. Small-molecule drugs, such as JAK inhibitors (tofacitinib, upadacitinib) and S1P receptor modulators (ozanimod), provide oral alternatives with rapid onset but entail systemic safety concerns.

Novel therapeutic avenues, including TYK2 and HDAC inhibitors, as well as nanotechnology-based delivery systems, show encouraging potential in early trials. Accessibility and affordability remain major obstacles, particularly in low- and middle-income regions, highlighting the need for biosimilars and international policy support.

Targeted molecular therapies have revolutionized IBD management by enabling precision treatment with enhanced efficacy and tolerability. Future efforts should focus on mitigating drug resistance, reducing costs, and integrating personalized medicine approaches to ensure global accessibility and sustainable disease control.